[Summary]GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding1/20TDnetPDF(175KB)
Shionogi Expands Rare Disease Presence with Planned Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS (edaravone) and IV RADIC12/22TDnetPDF(350KB)
Shionogi Receives Approval in Japan to Manufacture and Market ZURZUVAE Capsules 30 mg for the Treatment of Major Depressive Disorder 12/22TDnetPDF(124KB)
Notice regarding Completion of Succession of Japan Tobacco Inc.’s Pharmaceutical Business through Simplified Absorption-Type Company Split 12/1TDnetPDF(88KB)
(Corrections / Correction of Numerical Data) Corrections to the Consolidated Financial Results for the Second Quarter of Fiscal Year 2025 (IFRS)11/28TDnetPDF(178KB)
Action to Implement Management that is Conscious of Cost of Capital and Stock Price10/27TDnetPDF(770KB)
Notice Regarding the Execution of an Absorption-Type Company Split Agreement (Simplified Absorption-Type Split) for the Succession of Business9/25TDnetPDF(265KB)